Therapeutic drug monitoring (TDM) of conventional cytotoxic chemotherapies is strongly
supported yet poorly implemented in daily practice in hospitals. Analytical methods for the …

The prerequisites for the successful implementation of therapeutic drug monitoring (TDM)
include high inter-subject variation, low inter-occasion variation, narrow therapeutic index …

Background: Oral anticancer drugs show a high interpatient variability in pharmacokinetics
(PK), leading to large differences in drug exposure. For many of these drugs, exposure has …

There are few fields of medicine in which the individualisation of medicines is more
important than in the area of oncology. Under‐dosing can have significant ramifications due …

Historically, therapeutic drug monitoring (TDM) has mainly focused on measuring the level
of drugs and analyzing individualized pharmacokinetics. 1 However, during recent years …

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree
of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to …

Fixed dosing of oral targeted therapies is inadequate in the era of precision medicine.
Personalized dosing, based on pharmacokinetic (PK) exposure, known as therapeutic drug …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …

Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow
therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic …

Selecting the dose of a targeted cancer medicine that is most appropriate for a specific
individual is a rational approach to maximize therapeutic outcomes and minimize toxicity …